None listed
Conditions
Brief summary
A case-control design was used to examine the use of Hartmann, MoliCare® skin and body lotion to reduce skin tears among patients between two wards in an Australian private hospital. The two wards identified for the study was a medical/oncology ward which provided the control and the rehabilitation ward where the intervention was instituted. These two settings are considered comparable on the basis of patient demography as well as the level of patient acuity. Longitudinal data were collected for these settings both pre and post intervention period to determine the treatment’s efficacy and impact.
Interventions
Twice-daily application to the arms and legs of Hartmann, MoliCare® skin and body lotion with active ingredient of: creatine, essential fatty acids, amino acids and almond oil. Supports the skins own protection mechanisms and is moisturising. Water-in-oil emulsion.
The lotion is applied by a registered nurse working in the clinical setting and incorporating this modality into their daily routine of patient care. The lotion is applied at two 10 minute lotions applications per day - once in the a
Twice-daily application to the arms and legs of Hartmann, MoliCare® skin and body lotion with active ingredient of: creatine, essential fatty acids, amino acids and almond oil. Supports the skins own protection mechanisms and is moisturising. Water-in-oil emulsion. The lotion is applied by a registered nurse working in the clinical setting and incorporating this modality into their daily routine of patient care. The lotion is applied at two 10 minute lotions applications per day - once in the am and once in the PM. The intervention will not be personalised, titrated or adapted - each individual enrolled in the intervention arm of the study will receive twice daily application of moisturiser to the upper and lower limbs. The clinician documents that they have applied the moisturiser on the patients body by way of the - Skin Tear Clinical Trial: Moisturiser Application Chart.
Sponsors
St John of God (Ballarat)
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants eligible for inclusion were those: equal to or greater than 70 years of age, their admission did not require surgery, the patient reported to have no known allergy to nuts.
Exclusion criteria
Participants excluded from the study were those: not equal to or greater than 70 years of age, the patient reported an allergy to nuts.
Outcome results
None listed